home / stock / umrx / umrx short
Short Information | Cogent Biosciences (NASDAQ:UMRX)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 1,716,407 |
Total Actual Volume | 7,732,324 |
Short Trends | |
---|---|
Cover Days | 17 |
Short Days | 0 |
No Change Days | 3 |
Averages | |
---|---|
Average Short Volume | 85,820 |
Average Short Percentage | 20.26% |
Is there a UMRX Short Squeeze or Breakout about to happen?
See the UMRX Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
10-05-2020 | $2.38 | $2.35 | $2.41 | $2.3201 | 124,651 | 4,303 | 3.45% |
10-02-2020 | $2.37 | $2.34 | $2.4 | $2.26 | 389,011 | 95,412 | 24.53% |
10-01-2020 | $2.3 | $2.26 | $2.37 | $2.22 | 160,246 | 23,926 | 14.93% |
09-30-2020 | $2.25 | $2.34 | $2.401 | $2.25 | 207,492 | 23,900 | 11.52% |
09-29-2020 | $2.28 | $2.25 | $2.37 | $2.21 | 307,265 | 31,819 | 10.36% |
09-25-2020 | $2.31 | $2.28 | $2.38 | $2.2 | 241,357 | 11,860 | 4.91% |
09-24-2020 | $2.46 | $2.31 | $2.55 | $2.26 | 334,918 | 43,186 | 12.89% |
09-23-2020 | $2.66 | $2.5 | $2.69 | $2.46 | 288,942 | 36,569 | 12.66% |
09-22-2020 | $2.86 | $2.74 | $2.94 | $2.5 | 518,629 | 59,845 | 11.54% |
09-21-2020 | $2.98 | $2.85 | $3 | $2.76 | 170,023 | 49,870 | 29.33% |
09-18-2020 | $2.86 | $2.94 | $3.05 | $2.78 | 787,786 | 106,535 | 13.52% |
09-17-2020 | $2.89 | $2.86 | $2.99 | $2.7932 | 899,414 | 336,283 | 37.39% |
09-16-2020 | $2.68 | $2.83 | $2.95 | $2.67 | 651,849 | 149,081 | 22.87% |
09-15-2020 | $2.83 | $2.73 | $2.84 | $2.67 | 459,967 | 155,241 | 33.75% |
09-14-2020 | $2.34 | $2.7 | $2.75 | $2.34 | 494,782 | 46,464 | 9.39% |
09-11-2020 | $2.4 | $2.39 | $2.4949 | $2.3 | 236,797 | 35,551 | 15.01% |
09-10-2020 | $2.41 | $2.42 | $2.52 | $2.35 | 407,320 | 170,441 | 41.84% |
09-09-2020 | $2.26 | $2.41 | $2.469 | $2.245 | 364,155 | 167,939 | 46.12% |
09-08-2020 | $2.32 | $2.29 | $2.32 | $2.17 | 367,315 | 80,533 | 21.92% |
09-04-2020 | $2.17 | $2.2 | $2.31 | $2.05 | 320,405 | 87,649 | 27.36% |
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...